To study the relationship between pre-dialysis plasma sodium and blood pressure (BP), we performed an audit of patients who were on stable haemodialysis at St Bartholomew's and The Royal London Hospital from 1 June 2009 to 15 June 2010. There were 651 patients with 7445 dialysis sessions where both plasma biochemistry and BP were measured before haemodialysis. We found a significant association between plasma sodium and both systolic and diastolic BP. A 1 mmol l À1 increase in plasma sodium was related to 0.65/0.36 mm Hg increase in BP (Po0.001 for both systolic and diastolic BP) after adjusting for potential confounding factors, including weight gain between dialyses and plasma albumin, both of which are crude indices of extracellular fluid volume. A separate analysis excluding individuals who were on BP treatment showed a similar relationship, with a 1-mmol l À1 increase in plasma sodium associated with 0.82/0.56 mm Hg increase in BP (Po0.001 for both, N ¼ 177). These results provide further support for the accumulating evidence that plasma sodium has an important role in regulating BP, which may be independent of extracellular volume. Our findings in conjunction with other evidence suggest that small changes in plasma sodium could be an important mechanism for the beneficial effects of lower dialysate sodium and lower salt intake on BP in haemodialysis patients.
INTRODUCTION
There is compelling evidence demonstrating that dietary salt intake is a major regulator of blood pressure (BP). 1 The mechanisms whereby salt increases BP are not fully understood. The existing concepts focus on the tendency for an increase in extracellular fluid volume. Increasing evidence suggests that small increases in plasma sodium may have a direct effect on BP, independent of the associated change in extracellular volume. 2 --4 Clinical trials in hypertensive and normotensive individuals have shown that an increase or a decrease in salt intake causes parallel changes in plasma sodium, and the change in plasma sodium was weakly but significantly correlated with the change in systolic BP. 5 Several epidemiological studies in the general population have shown a positive association between plasma sodium and BP on individuals' usual diet. 6, 7 In individuals on haemodialysis, a low salt intake is very beneficial, particularly for the management of BP and interdialytic weight gain. 8 Plasma sodium is likely to have an important role for these beneficial effects of salt restriction. However, the evidence for this is not substantiated. To further study the relationship between plasma sodium and BP, we carried out a retrospective audit of medical records of individuals who were on stable haemodialysis at St Bartholomew's and The Royal London Hospital.
MATERIALS AND METHODS
In the Dialysis Unit of St Bartholomew's and The Royal London Hospital, all patients with chronic kidney disease undergoing haemodialysis routinely had their demographic data, BP and biochemistry recorded by nurses. The data were entered into an electronic database. For the present analysis, we selected patients who were on stable haemodialysis between 1 June 2009 and 15 June 2010. In stable haemodialysis patients, plasma sodium and other biochemistry measurements were usually performed before the mid-week dialysis sessions at monthly intervals. Therefore, our data consisted of repeated measurements of pre-dialysis plasma biochemistry and pre-dialysis BP at different dialysis sessions, and the duration between the dialysis session where our data were drawn and the previous dialysis session was one day only in all patients included in our analysis. The exclusion criteria were as follows: (1) individuals who were on haemodialysis owing to acute kidney injuries; (2) patients who had less than seven plasma biochemistry measurements during the study period from 1 June 2009 to 15 June 2010 or patients who required frequent plasma biochemistry monitoring (that is, more than 18 plasma biochemistry measurements during the same period); and (3) patients with systolic BP over 280 mm Hg or diastolic BP outside the range 20 --170 mm Hg.
BP was measured once in sitting position by automatic machines using Dinamap technology (Carescape V100 by GE, Freiburg, Germany). This is routine clinical practice. Weight gain between dialyses was estimated from the amount of fluid removed during dialysis. Biochemical measurements were performed by Roche modular units analyser (F.Hoffmann-La Roche Ltd, Basel, Switzerland). Plasma sodium and potassium were measured by indirect ion selective electrode methods, calcium was measured by the Calcium-O-Cresolphthalein Complexone method and albumin was measured by bromocresol green method. The coefficients of variation for all biochemistry analyses were o3%.
Statistical analysis
Taking into account of repeated measurements within individual patients, we used multilevel regression modelling. Univariate linear regression analysis was carried out to obtain crude association between plasma sodium (or other explanatory variables) and BP. Multiple regression analysis was performed to examine the relationship between plasma sodium and BP with adjustment for potential confounding factors including age, gender (male ¼ 1, female ¼ 0), ethnic group (white ¼ 1, other ¼ 0), weight gain between dialyses, plasma potassium, calcium and albumin, BP treatment (yes ¼ 1, no ¼ 0) and diabetes status (yes ¼ 1, no ¼ 0). In multilevel modelling, we used random effects models where the effect can vary between individuals. In other words, individuals can have different slopes.
To further exclude any potential confounding effects of BP-lowering agents on the relationship between plasma sodium and BP, we performed a separate analysis by excluding individuals who were on BP treatment. All analyses were performed using Stata version 10.
RESULTS

Results in all individuals
A total of 651 patients with 7445 observations (that is, 7445 dialysis sessions) were included in our analysis. The number of observations for each patient varied from 7 to 18 with a median of 11 during the study period from 1 June 2009 to 15 June 2010. Table 1 shows the characteristics of patients, the mean pre-dialysis BP and plasma biochemistry using patient-level data.
Univariate analysis showed that plasma sodium was significantly associated with both systolic and diastolic BP. An increase of 1 mmol l À1 in plasma sodium was related to an increase of 0.53 mm Hg in systolic (Po0.001) and 0.30 mm Hg in diastolic BP (Po0.001). These relationships were still significant after adjusting for age, gender, ethnic group, BP treatment, diabetes, weight gain between dialyses, plasma potassium, calcium and albumin ( Table 2 ). The effect of adjustment for these variables was to change the estimate of the increase in BP per 1 mmol l À1 increase in plasma sodium from 0.53 to 0.65 mm Hg for systolic BP and from 0.30 to 0.36 mm Hg for diastolic BP. In other words, after adjusting for confounding factors, an increase of 1 mmol l À1 in plasma sodium was associated with an increase of 0.65 mm Hg in systolic (Po0.001) and 0.36 mm Hg in diastolic BP (Po0.001).
In the multiple regression model, weight gain between dialyses, plasma calcium and albumin were also independently associated with both systolic and diastolic BP ( Table 2) . Plasma potassium was significantly associated with diastolic BP only. There was a significant positive association between age and systolic BP, whereas the association between age and diastolic BP was negative. The results for the categorical variables indicated that Caucasians had a lower systolic BP compared with other ethnic groups, individuals with diabetes had a higher systolic and lower diastolic BP compared with those without diabetes, and patients who were on BP treatment had a slightly higher systolic BP compared with those who were not on BP treatment (Table 2) .
Results in individuals who were not on BP-lowering drugs A total of 177 patients were not on BP treatment. There were 2030 observations (that is, dialysis sessions). Among these 177 individuals, 75 had systolic BP 4140 mm Hg and/or diastolic BP 490 mm Hg. In both univariate and multiple regression analysis, plasma sodium was significantly associated with both systolic and diastolic BP. After adjusting for age, gender, ethnic group, diabetes, weight gain between dialyses, plasma potassium, calcium and albumin, an increase of 1 mmol l À1 in plasma sodium was related to an increase of 0.82 mm Hg in systolic (Po0.001) and 0.56 mm Hg in diastolic BP (Po0.001).
In the multiple regression model, weight gain between dialyses and plasma albumin were significantly related to both systolic and diastolic BP (Table 3) . Plasma calcium was significantly associated with systolic BP, but not diastolic BP. Individuals with diabetes had a higher systolic BP compared with those without diabetes. Other variables including age, sex, ethnic group and plasma potassium were not significantly associated with either systolic or diastolic BP (Table 3) .
DISCUSSION
Our analysis is robust in that we included a relatively large number of haemodialysis patients, in particular, with repeated measurements rather than one single measurement of plasma sodium and BP. We found a significant association between plasma sodium and both systolic and diastolic BP. After adjusting for potential confounding factors, a 1-mmol l À1 increase in plasma sodium was related to an increase in BP of up to 0.82/0.56 mm Hg. A 3-mmol l À1 increase in plasma sodium, which has been shown to occur after consuming a typical Western meal, 9 would be associated with an increase in BP of up to 2.46/1.68 mm Hg.
Our analysis has a number of potential limitations. First, as in all observational studies, no causal relationship can be drawn. Second, the data, which we used in this analysis, were collected routinely rather than for research purpose. There might be concerns over the accuracy. However, any random errors would tend to attenuate the association. Interestingly we found a significant relationship between plasma sodium and BP. Finally, we could not exclude potential confounding effects of any unmeasured factors.
Our findings are in agreement with those observed in several other studies in the general populations. 6, 7 For example, Bulpitt et al. 6 reported a significant relationship between plasma sodium and systolic BP in a study involving 3578 London civil servants, with a 1-mmol l À1 increase in plasma sodium associated with a 1-mm Hg increase in systolic BP. However, a recent study in 2172 nonhypertensive Framingham Offspring Study participants found no significant association between plasma sodium and BP or the development of hypertension. 10 It is of note that none of these epidemiological studies was designed to study plasma sodium and therefore the timing of blood samples taken in relation to meals varied between individuals. It has been shown that a meal containing salt has an immediate and significant effect on plasma sodium. 9 There were also many other factors such as BP treatments, which affect the level of plasma sodium. It is therefore not surprising that some of the epidemiological studies did not show a significant association between plasma sodium and BP.
It is well established that extracellular fluid volume has a significant influence on BP. Our study showed that weight gain between dialyses and plasma albumin, both of which are crude indices of extracellular volume, were also significantly associated with BP. The results from our multiple regression analysis suggest an independent association of plasma sodium as well as extracellular fluid volume with BP. Stronger evidence for a direct role of plasma sodium in regulating BP comes from animal experiments. 3, 4 Using peritoneal dialysis in rats, Friedman et al. 3, 4 were able to change plasma sodium in an opposite direction to extracellular volume by altering sodium concentration of the dialysis fluid. When plasma sodium was increased by 10 --15 mmol l À1 , there was a rapid increase in BP despite a reduction in extracellular volume. When plasma sodium was decreased, there was a fall in BP despite an increase in extracellular volume.
In humans, it is difficult to study the effects of changes in plasma sodium without there being an associated change in extracellular volume. A recent study in patients on haemodialysis indicated that changes in plasma sodium could have an immediate and direct effect on BP. 11 A total of 10 individuals were studied, in random order, on two separate haemodialysis sessions, one with dialysate sodium set at 145 mmol l À1 and the other at 135 mmol l À1 , each for 2 h with no ultrafiltration. 11 This reduction in dialysate sodium concentration resulted in a significant decrease in plasma sodium of 3.4±0.3 mmol l À1 at 1 h (Po0.01) and 4.8 ± 0.3 mmol l À1 at 2 h (Po0.001). This was associated with a fall in systolic BP of 8 ± 3 mm Hg (Po0.05) at 1 h and 12±5 mm Hg (P ¼ 0.05) at 2 h. During the study, there was no fluid removed and there was no significant change in haematocrit, which is another crude index of extracellular volume. These results suggest that changes in plasma sodium could have a direct effect on BP, although small changes in extracellular volume due to the movements of fluid between intracellular and extracellular compartment could not be ruled out.
In many patients on haemodialysis, controlling BP is a major problem. Sodium balance is the cornerstone of good inter-dialysis BP control. 12 Although sodium balance in dialysis patients is determined by several factors, changes in dialysate sodium 11 Numerous studies have demonstrated that lower sodium dialysate, 13, 14 particularly in combination with a lower dietary salt intake, 15 --17 reduces interdialytic weight gain, improves BP control, decreases the severity of interdialytic symptoms and reduces cardiac volume loading. 17 Furthermore, a gradual reduction in dialysate sodium concentration, for example, from 140 to 135 mmol l À1 at a rate of 1 mmol l À1 every 3 --4 weeks, does not increase the frequency of substantive hypotension, headache, nausea, vomiting or dialysis morbidity. 17 In current clinical practice, dialysate sodium concentration varies between 135 and 145 mmol l À1 . Our results, combined with the evidence described above, support the use of a lower sodium concentration which would be associated with lower plasma sodium and could be beneficial in terms of BP control in individuals on haemodialysis.
The mechanisms whereby plasma sodium directly affects BP are not fully understood. Tissue culture experiments demonstrated that increasing bath sodium concentration by an amount similar to the increase in plasma sodium, which was seen with an increase in salt intake, caused marked cellular hypertrophy in both arterial smooth muscle and cardiac myocytes. 18 In cultured bovine and human endothelial cells, an increase in sodium concentration of culture medium reduced endothelial nitric oxide synthase activity, 19 stiffened endothelium and reduced nitric oxide release. 20 In addition, small changes in plasma sodium may directly affect the hypothalamus' control of BP through the local renin --angiotensin system. 2 In our analysis, there was a significant positive association between age and systolic BP and negative association between age and diastolic BP. This is likely to be due to the fact that the majority of our patients are over 50 years old. Other studies have shown that systolic BP increases continuously with age, whereas diastolic BP rises until B50 years old, and tends to level off or fall later in life. 21, 22 Additionally, many patients included in our study may have an increased arterial stiffness, which is associated with an increase in systolic BP, a decrease in diastolic BP, and therefore an increase in pulse pressure. 23, 24 As both age and diabetes are related to arterial stiffness, this may partially explain the contrasting association of these variables with systolic and diastolic BP (that is, positive association with systolic and negative association with diastolic BP) found in our study.
In the general population, there is an inverse relationship between plasma potassium and BP, that is, the higher the plasma potassium, the lower the BP. 6 In patients on haemodialysis, it has been reported that an acute decrease in plasma potassium because of haemodialysis resulted in 'rebound hypertension'. 25 However, there is no study that has looked at whether pre-dialysis plasma potassium is related to BP. Our study showed that plasma potassium was not independently associated with systolic BP, but there was a significant positive association between plasma potassium and diastolic BP. Further studies are needed to investigate the effect of plasma potassium on BP.
Our analysis also showed that plasma calcium was significantly related to BP. A 1-mmol l À1 increase in plasma calcium was associated with an increase in BP of up to 10/4 mm Hg. It appeared that for a 1-mmol l À1 increase in plasma calcium, there was a greater increase in BP compared with that with a 1-mmol l À1 increase in plasma sodium. However, a 1-mmol l À1 increase in plasma calcium represents a 44% increase from the baseline value of 2.27 mmol l À1 , whereas a 1-mmol l À1 increase in plasma sodium represents an increase of 0.7% only because the baseline plasma sodium was 141 mmol l À1 . Indeed, for a 1% increase in plasma sodium (that is, 1.41 mmol l À1 ), there would be an increase in BP of up to 1.16/0.79 mm Hg, whereas for a 1% increase in plasma calcium (that is, 0.02 mmol l À1 , which represents a more realistic change), there would be an increase in BP of up to 0.22/ 0.10 mm Hg. Clearly the impact of a change in plasma sodium on BP is much greater than that for plasma calcium. Our finding of a significant association between plasma calcium and BP is in agreement with those reported previously. 26, 27 In our analysis, there was a significant positive association between plasma albumin and BP. This finding is consistent with that found in the general population. 28 It is likely that this positive association may be due to the blood volume expanding effect of albumin. It has also been shown that, in patients on dialysis, higher plasma albumin has a cardiovascular protective effect, that is, higher plasma albumin is associated with a lower cardiovascular mortality. 29 It is well established that BP is a major predictor of cardiovascular mortality in these patients. In this aspect, a positive association between albumin and BP as found in our current analysis appears to be a contradiction. It is possible that these two variables may affect cardiovascular risk by unrelated mechanisms. 28 On the other hand, higher plasma albumin may attenuate the damaging effect of BP on the cardiovascular system.
In conclusion, our analysis demonstrates that plasma sodium is significantly related to BP in haemodialysis patients. This provides further support for the accumulating evidence 2, 5 that small changes in plasma sodium has an important role in regulating BP and could be an important mechanism whereby dietary salt intake affects BP. In patients on haemodialysis, it has been shown that lower sodium dialysate combined with a lower salt intake reduces interdialytic weight gain and improves BP control. 15 --17 Our findings in conjunction with other evidence, particularly that when dialysate sodium was altered, 11 suggest that a decrease in plasma sodium could play an important role for these beneficial effects. Well-controlled trials are needed to further study the role of plasma sodium and to assess the long-term impact of altering dialysate sodium concentration and salt intake on BP and cardiovascular outcomes in haemodialysis patients.
What is known about this topic
Increasing evidence suggests that plasma sodium may have an important role in regulating blood pressure.
What this study adds
In patients on haemodialysis, plasma sodium is significantly associated with both systolic and diastolic blood pressure, with a 1-mmol l À1 increase in plasma sodium related to an increase of 0.82/0.56 mm Hg in blood pressure after adjusting for confounding factors. Our findings in conjunction with other evidence, particularly that when dialysate sodium was altered, suggest that a decrease in plasma sodium could have an important part for the beneficial effects of lower sodium dialysate and lower salt intake on blood pressure control in haemodialysis patients.
